AIMOVIG is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is Erenumab.
Product ID | 55513-841_017de7ab-e700-44c1-a15d-8f1ad3fbb56f |
NDC | 55513-841 |
Product Type | Human Prescription Drug |
Proprietary Name | AIMOVIG |
Generic Name | Erenumab-aooe |
Dosage Form | Injection |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2018-05-22 |
Marketing Category | BLA / BLA |
Application Number | BLA761077 |
Labeler Name | Amgen Inc |
Substance Name | ERENUMAB |
Active Ingredient Strength | 70 mg/mL |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2018-05-22 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761077 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2018-05-22 |
Marketing End Date | 2021-01-31 |
Marketing Category | BLA |
Application Number | BLA761077 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2018-05-22 |
Ingredient | Strength |
---|---|
ERENUMAB | 70 mg/mL |
SPL SET ID: | b998ed05-94b0-47fd-b28f-cddd1e128fd8 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
55513-840 | AIMOVIG | erenumab-aooe |
55513-841 | AIMOVIG | erenumab-aooe |
55513-842 | AIMOVIG | erenumab-aooe |
55513-843 | AIMOVIG | erenumab-aooe |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
AIMOVIG 87325932 5536605 Live/Registered |
Amgen Inc. 2017-02-06 |
AIMOVIG 87079789 5530809 Live/Registered |
Amgen Inc. 2016-06-22 |